Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Posted by on Feb 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term safety and effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in high-risk patients with advanced classical Hodgkin lymphoma (cHL). The data showed that the A+AVD...

Read More

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Posted by on Feb 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...

Read More

Comparing BEAM to MITO/MEL regimens before autologous hematopoietic stem cell transplantation in patients with Hodgkin lymphoma.

Comparing BEAM to MITO/MEL regimens before autologous hematopoietic stem cell transplantation in patients with Hodgkin lymphoma.

Posted by on Feb 2, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) regimens before autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL). The study found that both regimens were similarly effective with fewer lung side effects with MITO/MEL.  Some...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reviewed treatment options to improve the outcomes of patients with Hodgkin’s lymphoma (HL) treated with an autologous stem cell transplant (ASCT).  Some background HL is a type of blood cancer. Patients with HL who do not respond to chemotherapy are given a transplant of their own healthy stem cells. The...

Read More

The effectiveness of chemotherapy and radiotherapy in nodular lymphocyte predominant Hodgkin lymphoma depending on disease stage

The effectiveness of chemotherapy and radiotherapy in nodular lymphocyte predominant Hodgkin lymphoma depending on disease stage

Posted by on Dec 31, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the effectiveness of chemotherapy and radiotherapy (CRT) in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).  This study concluded that combined CRT may be more effective in patients with early-stage NLPHL, particularly in older patients.  Some background...

Read More

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

Posted by on Dec 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of tandem autologous stem cell transplantation (ASCT) – reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in patients with high-risk (HR) relapsed Hodgkin lymphoma (HL). The main finding was that this approach was safe and effective in such patients. Some...

Read More

Comparing stem cell transplant from an identical donor to a half-matched donor in patients with Hodgkin Lymphoma.

Comparing stem cell transplant from an identical donor to a half-matched donor in patients with Hodgkin Lymphoma.

Posted by on Dec 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared stem cell transplants (SCT) from identical donors to half-matched donors in patients with Hodgkin Lymphoma (HL). The study found that patients who received a transplant from a half-matched donor had a better response and survival without cancer progression. Some background HL is a type of blood cancer. One...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.   This study concluded that this treatment path is feasible and a good treatment alternative for these patients.   Some background...

Read More